ICML 2023 | The changing role of alloSCT in DLBCL in the era of novel agents
Matthew Ulrickson, MD, Banner MD Anderson Cancer Center, Gilbert, AZ, briefly discusses the changing role of allogeneic stem cell transplantation (alloSCT) in diffuse large B-cell lymphoma (DLBCL) in the era of novel agents. Dr Ulrickson highlights the role of alloSCT in younger patients who are eligible for this approach, and further comments on the need to improve outcomes with novel CAR products and combination strategies. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So, allogeneic transplant in B-cell lymphomas, historically, as you mentioned, has had an important role for the care of patients. I don’t think it’s entirely excluded, but any time we get to expose patients to less toxicity, the better. I think that with CAR-T, not only in the relapsed/refractory setting, but hopefully as we are able to identify more activity in earlier lines of therapy, we can spare most patients from going to allogeneic transplant...
So, allogeneic transplant in B-cell lymphomas, historically, as you mentioned, has had an important role for the care of patients. I don’t think it’s entirely excluded, but any time we get to expose patients to less toxicity, the better. I think that with CAR-T, not only in the relapsed/refractory setting, but hopefully as we are able to identify more activity in earlier lines of therapy, we can spare most patients from going to allogeneic transplant. I will say that in those that have relapsed after a CAR-T that are otherwise young and good candidates for allo-transplant, that it is still a helpful strategy. But obviously it’s a known toxicity. You know, certainly the upfront morbidity and mortality that diminishes its role. So I think that hopefully we continue to get better still are some patients that aren’t fully met, you know, in terms of the outcomes with CAR-T, hopefully we can improve that with additional CAR products, combination strategies and continue to make the intensive therapies less and less needed.
Read more...
